ASH 2020: Results of a phase II study investigating Ixazomib combined with rituximab for first line treatment of indolent non-Hodgkin lymphomas.
Home / Resource Library / Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen